Alpha-Fetoprotein Testing Market Size Estimated to Reach $6.9 Billion by 2027

Alpha-Fetoprotein Testing Market Size Estimated to Reach $6.9 Billion by 2027

“Alpha-Fetoprotein Testing Market”
Alpha-fetoprotein (AFP) Testing Market Growth Is Being Driven by the Surging Count of Cancer Cases Which May Involve Chromosomal Abnormalities and Proliferating Technological Progress.

Alpha-fetoprotein (AFP) Testing Market size is estimated to reach $6.9 billion by 2027, growing at a CAGR of 5.3% during the forecast period 2022-2027. Alpha-fetoprotein (AFP) is a protein generated by the liver and yolk sac of a foetus. AFP has no typical function in mature grown-ups. The alpha-fetoprotein test (AFP) is a blood test carried out to assess, diagnose, or supervise foetal distress or foetal abnormalities. It can also discover certain liver ailments and certain cancers in mature grown-ups. Neural tube defects (NTDs) are severe congenital deformities. There have been investigations on complement factors and alpha-fetoprotein as biomarkers for noninvasive prenatal diagnosis of neural tube defects recommending that an ailment prediction model based on integrated complement factor and AFP data could act as a more precise technique of noninvasive prenatal NTD diagnosis. The alpha-fetoprotein (AFP) or foetal alpha globulin is thought to operate in the foetus in an identical role to that of serum albumin postnatally. AFP is combined in both the foetal liver and the yolk sac. The AFP test is a test that is carried out at the time of pregnancy of maternal blood or foetal amniotic fluid at 16-19 weeks of gestation. Alpha-fetoprotein (AFP) is a plasma protein generated by the embryonic yolk sac and the foetal liver. AFP levels in serum, amniotic fluid, and urine operate as a screening test for congenital disabilities, chromosomal abnormalities, and certain additional mature grown-up happening tumors and pathologies.

Alpha-fetoprotein (AFP) Testing Market Segment Analysis – By Cancer Type

The Alpha-fetoprotein (AFP) Testing Market based on cancer type can be further segmented into Liver Cancer, Testes Cancer, Biliary-Tract Cancer, Stomach Cancer, Pancreatic Cancer and Others. The Liver Cancer Segment held the largest market share in 2021. This growth is owing to the surging application of Alpha-fetoprotein (AFP) Testing as a screening test for liver cancer. Alpha-fetoprotein (AFP) is a plasma protein generated by the embryonic yolk sac and the foetal liver. AFP has a sensitivity of around 70% for liver cancer. The fact that two-thirds of liver cancers generate AFP is further propelling the growth of the Liver Cancer segment.

Furthermore, the Testes Cancer segment is estimated to grow with the fastest CAGR of 5.7% during the forecast period 2022-2027 owing to the increased application of AFP Test to assist in confirming or ruling out the outcomes of other tests where Alpha-fetoprotein (AFP) is a plasma protein generated by the embryonic yolk sac and the foetal liver.

Alpha-fetoprotein (AFP) Testing Market Segment Analysis – By End Use

The Alpha-fetoprotein (AFP) Testing Market based on end-use can be further segmented into Hospitals, Clinics, and Others. The Hospitals segment held the largest market share in 2021. This growth is owing to the progressive technologies accessible for treatment in conjunction with suitable care by specialists. Alpha-fetoprotein (AFP) Testing can be performed to detect neural tube defects and chromosomal abnormalities in the foetus. The supportive reimbursement policies and surging government initiatives for hospital treatments are further propelling the growth of this segment.

Furthermore, the Clinics segment is estimated to grow with the fastest CAGR of 5.9% during the forecast period 2022-2027 owing to the surging application of Alpha-fetoprotein screening in clinics to inspect the level of alpha-fetoprotein in the blood of the mothers at the time of pregnancy which could result in detection of neural tube defects and chromosomal abnormalities in the foetus.

Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=15383

Report Price: $ 4500 (Single User License)

Alpha-fetoprotein (AFP) Testing Market Segment Analysis – By Geography

The Alpha-fetoprotein (AFP) Testing Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Alpha-fetoprotein (AFP) Testing Market) held the largest share with 38% of the overall market in 2021. The growth of this region is owing to the increasing predominance of autoimmune ailments and cancer in the region. Alpha-fetoprotein (AFP) Testing is performed to detect neural tube defects and chromosomal abnormalities in the foetus. The upsurge in R&D activities to develop novel treatments for numerous ailments is further propelling the growth of the Alpha-fetoprotein (AFP) Testing Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the rising pervasiveness of incessant ailments like cancer in the Asia-Pacific region. Alpha-fetoprotein (AFP) is a plasma protein generated by the embryonic yolk sac and the foetal liver. The enormous patient pool and heightening spending on healthcare are further fuelling the progress of the Alpha-fetoprotein (AFP) Testing Market in the Asia-Pacific region.

Alpha-fetoprotein (AFP) Testing Market Drivers

Surging Applications Of Alpha-Fetoprotein For Detection Of Neural Tube Defects And Chromosomal Abnormalities Are Projected To Drive The Growth Of Alpha-fetoprotein (AFP) Testing Market

Since its launch into obstetric practice, maternal serum alpha-fetoprotein (MSAFP) screening has evolved into the first noninvasive biochemical test to offer information concerning the foetus. Its utility has extended from recognizing pregnancies at a soaring hazard of neural tube defects to discovering additional structural and chromosomal abnormalities of the foetus. MSAFP screening reduces morbidity and mortality by advancing access to earlier diagnosis, allowing families to make informed reproductive selections, and planning suitable strategies for prenatal care and delivery. Normal generation of alpha-fetoprotein (AFP) is rare to foetal development, making it a perfect marker for early foetal investigation. The surging applications of alpha-fetoprotein are therefore fuelling the growth of the Alpha-fetoprotein (AFP) Testing Market during the forecast period 2022-2027.

Proliferating Applications Of Alpha-Fetoprotein For Treatment Of Autoimmune Ailments And Cancer Are Expected To Boost The Demand Of Alpha-fetoprotein (AFP) Testing Market

Alpha-fetoprotein is a shuttle protein that transfers nutrients by way of receptor-mediated endocytosis to embryonic cells. In mature grown-ups, alpha-fetoprotein can shuttle medications into alpha-fetoprotein receptor-positive myeloid-derived suppressors, regenerating and also cancer cells. Medications with a high-binding affinity to alpha-fetoprotein can stimulate or drain targeted cells. Myeloid-derived suppressor cells stimulation results in immune suppression that can be utilized for treating autoimmune ailments. On the other hand, toxins transferred by alpha-fetoprotein can harm myeloid-derived suppressor cells and thereupon discharge innate and adaptive immunity to demolish cancer cells. Innate immunity natural killers decrease cancer stem cells and metastases. The novel alpha-fetoprotein medication noncovalent complexes for immunotherapy alter the local immune balance and hold potential in oncology, autoimmune and infectious ailments treatment, inflammation, transplantation, and vaccination. The proliferating applications of alpha-fetoprotein for the treatment of autoimmune ailments and cancer apart from detecting neural tube defects are driving the growth of the Alpha-fetoprotein (AFP) Testing Market during the forecast period 2022-2027.

Direct Purchase @ https://www.industryarc.com/purchasereport.php?id=15383

Alpha-fetoprotein (AFP) Testing Market Challenges

Existence Of False Positive Results And False Negative Results Are Hampering The Growth Of The Alpha-fetoprotein (AFP) Testing Market:

A multiple marker test is not diagnostic. This means that it is not 100% precise. It is just a screening test to observe those who may require greater tests for their pregnancy. There may be false positive outcomes. These outcomes demonstrate an issue when the baby is in fact healthy. Similarly, there may be false-negative outcomes. False-negative outcomes demonstrate that all is normal when in fact the baby does have a health issue. These issues are thus hampering the growth of the Alpha-fetoprotein (AFP) Testing Market.

Alpha-fetoprotein (AFP) Testing Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and R&D Activities are key strategies adopted by players in the Alpha-fetoprotein (AFP) Testing Market. Key companies of this market are:

Abbott Laboratories
Labcorp
Roche Diagnostics
Thermo Fisher Scientific
MP Biomedicals
Bio-Rad Laboratories
Beckman Coulter
Siemens Healthcare
Kreatech Diagnostics
GeneCopoeia, Inc

Recent Developments

In December 2021, Roche declared the introduction of NAVIFY® Oncology Hub, its most-recent digital solution to further improve clinical decision backing and workflow optimization for oncologists and oncology care teams. Oncologists frequently encounter incomplete patient records and data silos across multiple IT systems. This makes it hard to discover and accumulate all relevant data to acquire the complete picture of the patient’s health history and evaluate every case holistically.

In November 2021, Roche declared the introduction of the cobas® 5800 System, a novel molecular laboratory tool, in countries receiving the CE mark. Testing is one of the earliest lines of defense to safeguard a patient’s general well-being and is vital in speedily guiding their treatment. The cobas 5800 System assists in attending to challenges that the laboratories are encountering from a boost in patient testing, reimbursement complications, and the requirement for a more diverse testing menu while offering significant and timely outcomes.

In April 2020, Abbott introduced its third test for coronavirus (COVID-19) and is shipping tests to hospitals across the U.S. The test is a serology test – also termed an antibody test – which could be a crucial next step in combating this virus.  Abbott’s test assists to discover the IgG antibody to SARS-CoV-2.

Related Report

Genetic Testing Market

https://www.industryarc.com/Report/15123/genetic-testing-market.html

For more Lifesciences and Healthcare Market reports, please click here

About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.

Media Contact
Company Name: IndustryARC
Contact Person: Mr. Venkat Reddy
Email: Send Email
Phone: (+1) 970-236-3677
Address:Madhapur
City: Hyderabad
Country: India
Website: https://www.industryarc.com/